Shattuck Labs, Inc. (NASDAQ:STTK) Short Interest Update

Shattuck Labs, Inc. (NASDAQ:STTK) was the target of a large increase in short interest in June. As of June 15th, there was short interest totalling 2,171,700 shares, an increase of 21.3% from the May 31st total of 1,790,000 shares. Currently, 5.3% of the company’s stock are short sold. Based on an average daily trading volume, of 331,500 shares, the days-to-cover ratio is presently 6.6 days.

Wall Street Analysts Forecast Growth

STTK has been the subject of several recent analyst reports. BTIG Research downgraded Shattuck Labs from a “buy” rating to a “neutral” rating in a research note on Monday, June 17th. HC Wainwright decreased their target price on Shattuck Labs from $28.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, June 20th. Needham & Company LLC dropped their price target on shares of Shattuck Labs from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, June 14th. Finally, Citigroup decreased their price objective on shares of Shattuck Labs from $10.00 to $9.00 and set a “buy” rating for the company in a report on Monday, June 17th.

Insider Activity at Shattuck Labs

In other Shattuck Labs news, CEO Taylor Schreiber acquired 14,400 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The shares were purchased at an average price of $3.47 per share, with a total value of $49,968.00. Following the completion of the transaction, the chief executive officer now owns 34,502 shares in the company, valued at $119,721.94. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 10.50% of the stock is currently owned by company insiders.

Institutional Trading of Shattuck Labs

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in shares of Shattuck Labs by 38.2% during the 1st quarter. Vanguard Group Inc. now owns 1,819,926 shares of the company’s stock worth $16,270,000 after purchasing an additional 502,860 shares during the period. Franklin Resources Inc. acquired a new stake in Shattuck Labs during the fourth quarter worth about $11,663,000. Pinnacle Associates Ltd. increased its stake in Shattuck Labs by 13.9% during the first quarter. Pinnacle Associates Ltd. now owns 521,246 shares of the company’s stock valued at $4,660,000 after acquiring an additional 63,800 shares during the period. Monashee Investment Management LLC acquired a new position in Shattuck Labs in the 4th quarter valued at approximately $713,000. Finally, SG Americas Securities LLC lifted its position in shares of Shattuck Labs by 4.8% in the 1st quarter. SG Americas Securities LLC now owns 39,377 shares of the company’s stock worth $352,000 after acquiring an additional 1,788 shares during the period. 58.74% of the stock is owned by institutional investors.

Shattuck Labs Stock Performance

NASDAQ STTK opened at $3.99 on Tuesday. The stock has a 50-day simple moving average of $7.59 and a 200 day simple moving average of $8.41. Shattuck Labs has a twelve month low of $1.33 and a twelve month high of $11.76. The stock has a market capitalization of $189.72 million, a PE ratio of -2.07 and a beta of 1.74.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.08. The company had revenue of $1.15 million during the quarter, compared to analyst estimates of $0.30 million. Shattuck Labs had a negative return on equity of 64.85% and a negative net margin of 3,133.63%. Shattuck Labs’s revenue for the quarter was up 2200.0% on a year-over-year basis. As a group, equities research analysts forecast that Shattuck Labs will post -1.56 EPS for the current fiscal year.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.